Psychologic Test Responses and Methylphenidate

  • D. S. Janowsky
  • L. Huey
  • L. Storms
Part of the Advances in Behavioral Biology book series (ABBI, volume 21)


Janowsky, El-Yousef and Davis (1973a) have previously described the immediate activation or worsening of pre-existing psychotic symptoms in actively psychotic schizophrenics by a small (0.5 mg/kg) dose of methylphenidate. This phenomena differs from the predominantly paranoid psychosis occurring in normals, as well as psychotics, which follows chronic high dose amphetamine administration (Griffith, Cavanaugh, Held and Oates, 1972). Methylphenidate-induced psychosis activation does not occur in patients receiving placebo injections, in remitted schizophrenic patients, or in nor-mals (Janowsky et al., 1973a). Also, intravenous methylphenidate has been found by Janowsky and Davis (1974) to be about 1.5 times as effective as d-amphetamine and 3 times as effective as 1-amphetamine in activating psychotic symptoms. Due to these interrelationships, and methylphenidate’s specific biochemical effects on brain dopamine in rats (Ferris, Tang, and Maxwell, 1972; Snyder, Taylor, Coyle and Meyerhoff, 1970; Yaryura-Tobias, Diamond and Merlis, 1970; Angrist, Sathananthan and Gershon, 1973; Scheel-Kruger, 1971), Janowsky et al. (1973a; 1974) have implied a dopaminergic etiology to the phenomena of psychostimulant-induced psychosis activation in schizophrenics.


Schizophrenic Patient Word Association Projective Test Brief Psychiatric Rate Scale Score Word Association Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Angrist, B., Sathananthan, G., and Gershon, S.: Behavioral effects of L-Dopa in schizophrenic patients, Psychopharmacologia 31, 1–12 (1973).PubMedCrossRefGoogle Scholar
  2. Bleuler, E.: Dementia Praecox or the Group of Schizophrenias (Mono-graph Series on Schizophrenia Number 1 ). New York: International University Press, 1950.Google Scholar
  3. Coyle, J.T. and Snyder, S.H.: Catecholamine uptake by synaptosomes in homogenates of rat brain: Stereospecificity in different areas, J. Pharmac. exp. Ther. 170, 221–231 (1969).Google Scholar
  4. Ferris, R., Tang, F., and Maxwell, R.: A comparison of the capacities of isomers of amphetamine, deoxypiradrol and methylphen-idate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta, J. Pharmac. exp. Ther. 181, 407–416 (1972).Google Scholar
  5. Gorham, D.: Verbal abstraction in psychiatric patients: Assay of impairment utilizing proverbs, J. ment. Sci. 107, 52–59 (1961).PubMedGoogle Scholar
  6. Griffith, J., Cavanaugh, J., Held, J., and Oates, J.: Dextroamphetamine: Evaluation of psychotomimetic properties in man, Archs gen. Psychiat. 26, 97–100 (1972).CrossRefGoogle Scholar
  7. Harris, J. and Baldessarini, R.: Uptake of (3H)-catecholamines by homogenates of rat corpus striatum and cerebral cortex: Effects of amphetamine analogues, Neuropharmacology 12, 669679 (1973).Google Scholar
  8. Heikkila, R.E., Orlansky, H., Mytilineou, C., and Cohen, G.: Amphetamine: Evaluation of d-and 1-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex, J. Pharmac. exp. Ther. 194, 47–56 (1975).Google Scholar
  9. Holtzman, W.: Ink Blot Technique: Administration and Scoring Guide. Minneapolis: University of Minnesota Press, 1964.Google Scholar
  10. Janowsky, D.S., El-Yousef, M.K., Davis, J.M., and Sekerke, H.J.: Cholinergic antagonism of methylphenidate-induced stereotyped behavior, Psychopharmacologia 27, 295–303 (1972).CrossRefGoogle Scholar
  11. Janowsky, D.S., E1-Yousef, M.K., and Davis, J.M.: Provocation of schizophrenic symptoms by intravenous administration of methylphenidate, Archs gen. Psychiat. 28, 185–191 (1973a).CrossRefGoogle Scholar
  12. Janowsky, D.S., El-Yousef, M.K., and Davis, J.: Antagonistic effects of physostigmine and methylphenidate in man, Am. J. Psychiat. 130, 1370–1376 (1973b).PubMedGoogle Scholar
  13. Janowsky, D.S. and Davis, J.M.: Dopamine, psychomotor stimulants, and schizophrenia: Effects of methylphenidate and the stereo-isomers of amphetamine in schizophrenics. In: Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes. Usdin, E., Ed., pp. 317–323. New York: Raven Press, 1974.Google Scholar
  14. Ladinsky, H., Consolo, S., Bianchi, S., Samanin, R., and Ghezzi, D.: Cholinergic-dopaminergic interaction in the striatum: The effect of 6-hydroxydopamine or pimozide treatment on the increased striatal acetylcholine levels induced by apomorphine, piribedil and d-amphetamine, Brain Res. 84, 221–226 (1975).PubMedCrossRefGoogle Scholar
  15. Moore, K., Carr, L., and Dominic, J.: Functional significance of amphetamine induced release of brain catecholamines. In: Amphetamines and Related Compounds. Costa, E. and Garattini, S., Eds., pp. 371–384. New York: Raven Press, 1970.Google Scholar
  16. Palermo, D. and Jenkins, J.: Word Association Norms: Grade School Through College. Minneapolis: University of Minnesota Press, 1974.Google Scholar
  17. Phillips, A.G., Brooke, S.M., and Fibiger, H.C.: Effects of amphet-amine isomers and neuroleptics on self-stimulation from the nucleus accumbens and dorsal noradrenergic bundle, Brain Res. 85, 13–22 (1975).PubMedCrossRefGoogle Scholar
  18. Scheel-Krüger, J.: Central effects of anticholinergic drugs measured by the apomorphine gnawing test in mice, Acta pharmac. 28, 1–16 (1970).CrossRefGoogle Scholar
  19. Scheel-Krüger, J.: Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain, Eur. J. Pharmacol. 14, 47–59 (1971).PubMedCrossRefGoogle Scholar
  20. Singh, M.M. and Kay, S.R.: A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia: Theoretical imlications for potency differences among neuroleptics, Psychopharmacologia 43, 103–113 (1975).PubMedCrossRefGoogle Scholar
  21. Snyder, S., Taylor, J., Coyle, J., and Meyerhoff, B.: The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs, Am. J. Psychiat. 127, 199–207 (1970).PubMedGoogle Scholar
  22. Storms, L. and Broen, W.: A theory of schizophrenic behavioral disorganization, Archs gen. Psychiat. 20, 129–144 (1969).CrossRefGoogle Scholar
  23. Thornburg, J. and Moore, K.: Dopamine and norepinephrine uptake by rat brain synaptosomes: Relative inhibitory potencies of 1- and d-amphetamine and amantadine, Res. Commun. Chem. Path. Pharmac. 5, 81–89 (1973).Google Scholar
  24. Trabucchi, M., Cheney, D.S., Racagni, G., and Costa, E.: In vivo inhibition of striatal acetylcholine turnover by L-Dopa, apomorphine and (+)-amphetamine, Brain Res. 85, 130–134 (1975).PubMedCrossRefGoogle Scholar
  25. Von Voightlander, P. and Moore, K.: Involvement of nigro-striatal neurons in the in vivo release of dopamine by amphetamine, amantadine and tyramine, J. Pharmac. exp. Ther. 184, 542552 (1975).Google Scholar
  26. Yaryura-Tobias, J., Diamond, B., and Merlis, S.: The action of L-Dopa on schizophrenic patients, Curr. ther. Res. 12, 528–531 (1970).PubMedGoogle Scholar
  27. Ziance, R.J., Azzaro, A.J., and Rutledge, C.O.: Characteristics of amphetamine-induced release of norepinephrine from rat cerebral cortex in vitro, J. Pharmac. exp. Ther. 182, 284–294 (1972).Google Scholar

Copyright information

© Plenum Press, New York 1977

Authors and Affiliations

  • D. S. Janowsky
    • 1
  • L. Huey
    • 1
  • L. Storms
    • 1
  1. 1.Department of PsychiatryUniversity of California at San Diego School of MedicineLa JollaUSA

Personalised recommendations